Eventide Asset Management’s Aptose Biosciences, Inc. APTO Stock Holding History

Eventide Asset Management’s Portfolio APTO Stock Details APTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,109	Closed	-$7.63M	–	164
2021 Q2	$7.63M	Hold	5,109	–	–	0.1%	126
2021 Q1	$13.7M	Hold	5,109	–	–	0.2%	106
2020 Q4	$10.1M	Buy	+5,109	New	+$12M	0.15%	108

Other funds holding APTO

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

P.A.W. Capital Greenwich, Connecticut $36.7M AUM 6.81% 1-Year Est. Return

Eventide Asset Management's APTO Position: Q3 2021 in Review

Eventide Asset Management sold out of Aptose Biosciences, Inc. (APTO) in Q3 2021, closing a stake of 5,109 shares — an estimated $7.63M sold.

Eventide Asset Management first reported a position in APTO in Q4 2020 and held it in 3 quarters. The position peaked at $13.7M in Q1 2021. 64 funds tracked by Wall St. Rank hold APTO as of Q3 2021.

Eventide Asset Management reported no remaining Aptose Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
Eventide Asset Management sold 5,109 Aptose Biosciences, Inc. shares in Q3 2021, an estimated $7.63M.
Eventide Asset Management first reported a position in Aptose Biosciences, Inc. in Q4 2020 and held it in 3 quarters.
Eventide Asset Management's Aptose Biosciences, Inc. position peaked at $13.7M in Q1 2021.
64 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q3 2021.

Based on Eventide Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.